TNFRSF9 and neoplasm: One possible approach to treating patients with high tumor PD-L1 expression and associated low CD8:Foxp3 T-cell ratios is the addition of immune-stimulatory molecules, such as agonists of CD27, GITR, 4-1BB, OX40 and others.